Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06229353 · ClinicalTrials.gov registry record
Developing and Evaluating a Novel Approach to Improve HPV Vaccination Coverage Among High-risk, Under-immunized Adults Via the Emergency Department
A clinical trial, sponsored by University of Alabama at Birmingham.
- Terminated
- Registry status
- 34
- Enrollment target
NCT06229353 is a clinical trial that was terminated before completion, run by University of Alabama at Birmingham. The registered enrollment target is 34 participants.
The verdict
NCT06229353 was terminated before completion, sponsored by University of Alabama at Birmingham.
- TERMINATED
- Registry status
- 34 participants
- Enrollment target
Study Summary
To determine if the emergency department (ED) setting offers a viable space for improving HPV vaccination coverage among 18 to 45-year-old adults who have not yet received human papilloma virus (HPV) vaccination or who did not complete the vaccine series. This study will develop, pilot and evaluate an ED-based HPV vaccination protocol and program for ED patients aged 18-26 (for whom catch-up HPV vaccination is routinely recommended by the CDC) and separately for patients aged 27-45 (for whom it may be recommended under shared decision making, SDM).
Interventions
- BIOLOGICAL Gardasil 9
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2024-08-08 |
| Est. Completion | 2025-07-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06229353
The ClinicalTrials.gov registry entry for NCT06229353 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Gardasil 9 is the first listed.
NCT06229353 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06229353 about?
NCT06229353 is a clinical study titled "Developing and Evaluating a Novel Approach to Improve HPV Vaccination Coverage Among High-risk, Under-immunized Adults Via the Emergency Department". To determine if the emergency department (ED) setting offers a viable space for improving HPV vaccination coverage among 18 to 45-year-old adults who have not yet received human papilloma virus (HPV) vaccination or who did not complete the vaccine series. This study will develop, pilot and evaluate ...
What is the current status of trial NCT06229353?
This trial is currently terminated. The enrollment target is 34 participants. The study started on 2024-08-08. Estimated completion is 2025-07-30.
What interventions are being tested in trial NCT06229353?
The interventions under investigation include: Gardasil 9 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06229353?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.